Research and Markets: Malignant Neoplasms - Pipeline Review, H1 2013

Research and Markets: Malignant Neoplasms - Pipeline Review, H1 2013

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Global Markets Direct's, 'Malignant Neoplasms - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Neoplasms, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Neoplasms.

- A snapshot of the global therapeutic scenario for Malignant Neoplasms.

- A review of the Malignant Neoplasms products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Malignant Neoplasms pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- News and deals relating to the products.

- Identify and understand important and diverse types of therapeutics under development for Malignant Neoplasms.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Malignant Neoplasms pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.